On April 22, 2021 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that it will host its virtual R&D Day for analysts and investors at 10:00 a.m. – 1:00 p.m. ET on Wednesday, April 28, 2021 (Press release, Trillium Therapeutics, APR 22, 2021, View Source [SID1234578359]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D Day agenda will include:

·a clinical update for TTI-622 and TTI-621,
·new strategic priorities in terms of target indications and drug combinations across hematologic malignancies and solid tumors, and
·updated milestones and guidance for 2021.

More information on Trillium’s R&D Day will be available at: ir.trilliumtherapeutics.com/events-and-presentations/RD-Day

You can join the webcast at: View Source